The North America Digital Diabetes Management Market is expected to witness market growth of 11.4% CAGR during the forecast period (2022-2028).
Patients and providers generate enormous volumes of data from a variety of sources, including electronic medical records, insulin pumps, sensors, glucometers, and other wearables, as well as developing genomic, proteomic, metabolomic, and microbiomic data. Using motivational tools and adding incentives from social media and gaming approaches, a variety of digital tools and apps have been developed to help patients make informed decisions and improve their compliance. Digital advancements that sift through the massive volumes of patient-generated data help healthcare teams (HCTs) and health administrators.
Data is collected, integrated, evaluated, and shown in a self-explanatory manner, indicating key patterns and things that need to be addressed. The use of decision support systems can suggest data-driven measures that, in most cases, require final consent from the patient or physician before being carried out, and that, once executed, can enhance patient outcomes. The goal of the digital diabetes clinic is to combine all digital patient data and give specifically tailored virtual or face-to-face visits to individuals who need them the most.
North America dominated the market in 2018, owing to rising smart consumer device penetration and AI-based service innovation. Furthermore, concepts such as the Internet of Things, big data, machine learning, and robotics are in the next stage of digitalization in the region. As a result, during the projected period, these digital technologies are expected to boost the regional market. Due to new product launches and the presence of prominent competitors in the region, North America is expected to be a key market for digital diabetes management applications and devices.
The US market dominated the North America Digital Diabetes Management Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $7,447.5 million by 2028. The Canada market is anticipated to grow at a CAGR of 14% during (2022 - 2028). Additionally, The Mexico market is expected to witness a CAGR of 13% during (2022 - 2028).
Based on Type, the market is segmented into Wearables and Handheld Devices. Based on Product & Service, the market is segmented into Devices (Continuous Glucose Monitoring (CGM) Systems, Smart Glucose Meters, Smart Insulin Pens, and Smart Insulin Pumps/Closed-loop Pumps & Smart Insulin Patches), Application (Diabetes & Blood Glucose Tracking Apps and Obesity & Diet Management Apps), Data Management Software & Platforms, and Services. Based on End User, the market is segmented into Self/Home Healthcare, Hospitals & Specialty Diabetes Clinics, and Academic & Research Institutes. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Medtronic PLC, Abbott Laboratories, Terumo Corporation, F. Hoffmann-La Roche Ltd., DexCom, Inc., Novo Nordisk A/S, ACON Laboratories, Inc., Bayer AG, B. Braun Melsungen AG, and Azumio, Inc.
Patients and providers generate enormous volumes of data from a variety of sources, including electronic medical records, insulin pumps, sensors, glucometers, and other wearables, as well as developing genomic, proteomic, metabolomic, and microbiomic data. Using motivational tools and adding incentives from social media and gaming approaches, a variety of digital tools and apps have been developed to help patients make informed decisions and improve their compliance. Digital advancements that sift through the massive volumes of patient-generated data help healthcare teams (HCTs) and health administrators.
Data is collected, integrated, evaluated, and shown in a self-explanatory manner, indicating key patterns and things that need to be addressed. The use of decision support systems can suggest data-driven measures that, in most cases, require final consent from the patient or physician before being carried out, and that, once executed, can enhance patient outcomes. The goal of the digital diabetes clinic is to combine all digital patient data and give specifically tailored virtual or face-to-face visits to individuals who need them the most.
North America dominated the market in 2018, owing to rising smart consumer device penetration and AI-based service innovation. Furthermore, concepts such as the Internet of Things, big data, machine learning, and robotics are in the next stage of digitalization in the region. As a result, during the projected period, these digital technologies are expected to boost the regional market. Due to new product launches and the presence of prominent competitors in the region, North America is expected to be a key market for digital diabetes management applications and devices.
The US market dominated the North America Digital Diabetes Management Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $7,447.5 million by 2028. The Canada market is anticipated to grow at a CAGR of 14% during (2022 - 2028). Additionally, The Mexico market is expected to witness a CAGR of 13% during (2022 - 2028).
Based on Type, the market is segmented into Wearables and Handheld Devices. Based on Product & Service, the market is segmented into Devices (Continuous Glucose Monitoring (CGM) Systems, Smart Glucose Meters, Smart Insulin Pens, and Smart Insulin Pumps/Closed-loop Pumps & Smart Insulin Patches), Application (Diabetes & Blood Glucose Tracking Apps and Obesity & Diet Management Apps), Data Management Software & Platforms, and Services. Based on End User, the market is segmented into Self/Home Healthcare, Hospitals & Specialty Diabetes Clinics, and Academic & Research Institutes. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Medtronic PLC, Abbott Laboratories, Terumo Corporation, F. Hoffmann-La Roche Ltd., DexCom, Inc., Novo Nordisk A/S, ACON Laboratories, Inc., Bayer AG, B. Braun Melsungen AG, and Azumio, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Type
- Wearables
- Handheld Devices
By Product & Service
- Devices
- Continuous Glucose Monitoring (CGM) Systems
- Smart Glucose Meters
- Smart Insulin Pens
- Smart Insulin Pumps/Closed-loop Pumps & Smart Insulin Patches
- Application
- Diabetes & Blood Glucose Tracking Apps
- Obesity & Diet Management Apps
- Data Management Software & Platforms
- Services
By End User
- Self/Home Healthcare
- Hospitals & Specialty Diabetes Clinics
- Academic & Research Institutes
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Medtronic PLC
- Abbott Laboratories
- Terumo Corporation
- F. Hoffmann-La Roche Ltd.
- DexCom, Inc.
- Novo Nordisk A/S
- ACON Laboratories, Inc.
- Bayer AG
- B.Braun Melsungen AG
- Azumio, Inc.
Unique Offerings from KBV Research
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Competition Analysis - Global
Chapter 4. North America Digital Diabetes Management Market by Type
Chapter 5. North America Digital Diabetes Management Market by Product & Service
Chapter 6. North America Digital Diabetes Management Market by End User
Chapter 7. North America Digital Diabetes Management Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- Medtronic PLC
- Abbott Laboratories
- Terumo Corporation
- F. Hoffmann-La Roche Ltd.
- DexCom, Inc.
- Novo Nordisk A/S
- ACON Laboratories, Inc.
- Bayer AG
- B. Braun Melsungen AG
- Azumio, Inc.
Methodology
LOADING...
